Seoul Semiconductor Applies Violeds Disinfection Technology to Luxury Sedan Genesis G90
UV-C disinfection technology solution, Violeds, developed by Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a globally recognized optical semiconductor manufacturer, is installed in the console boxes of Genesis, a global luxury vehicle brand, with the disinfection technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005088/en/
[Photo 1] Violeds UV-C LEDs are applied inside of the armrest console box of Genesis G90 (Graphic: Business Wire)
Luxury sedan Genesis G90 was officially launched for the market in the first half of 2022. The armrest console box in the back of G90 is equipped with UV-C LED lamps to disinfect passengers’ belongings in preparation for the era of COVID-19. Seoul Semiconductor’s violeds technology is applied to these UV-C LED lamps. Depending on its models, 6 to 12 LED lamps are installed, eliminating up to 99.9% of harmful germs (E.coli, staphylococcus aureus, and pneumobacilli) in personal possessions within 10 minutes after the lid is closed.
* The test results offered by Hyundai Motor Company and validated by Intertek, a global testing and certification agency, are subject to change depending on real environments
Violeds is a patented solution developed and massively applied for the first time in the world by Seoul Viosys, Seoul Semiconductor’s subsidiary. It prevents the growth of germs and bacteria with UV LEDs. According to 2021 data from Omdia, a market research agency, Seoul Viosys ranks 1st in the world in UV LED technology.
Seoul Viosys has successfully developed air sterilization solutions, as well as violeds-based surface disinfection systems. In August 2021, the company held a press conference to release its solution to prevent the spread of the delta variant, which is able to remove 99% of indoor airborne viruses. Based on the test results, it demonstrated the process of disinfecting auto air conditioning systems at CES 2022, making its technological prowess be globally recognized.
“We are very pleased to supply violeds-based UVC LEDs to global luxury brand Genesis G90. Operating our own auto air and surface sterilization lab, we have done our utmost to further develop UV LED disinfection technology. As a result, violeds technology will take the lead in expanding vehicle indoor healthcare markets in the world,” said a Seoul Semiconductor official.
He added, “acquiring the AEC-Q102 certification, the automotive LED reliability standard, violeds technology will become an optimized solution for auto healthcare projects required by clients.”
Based on more than 30 years of R&D experiences in optical semiconductor, Seoul Semiconductor has successfully established a product portfolio with all wavelength bands (200 ~ 1,600nm) from UV to visible rays and IR (VCSEL) applicable to auto solutions, holding 18,000 tech patents and thereby maintaining technological superiority in global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005088/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jung
Tel: +82-70-4391-8555
Email: jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release
TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom